butabarbital decreases outcomes of sufentanil SL by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Check Closely. Coadministration of CYP3A4 inducers could lower sufentanil levels and efficacy, probably precipitating withdrawal syndrome in patients who may have made physical dependence to sufentanil. Discontinuation of conc